| 1% | Les prix à la consommation en France augmentent de 1% en Juin 2025- Insee |
|
Accueil > Actualité
Novartis: positive data for breast cancer drug
(CercleFinance.com) - Novartis has announced positive top-line results from an interim analysis of NATALEE, a phase III trial evaluating its Kisqali (ribociclib), in combination with hormone therapy, in early HR+/HER2- breast cancer at risk of recurrence.
The Swiss healthcare group says that the independent data monitoring committee recommended stopping the trial early because the primary endpoint of invasive disease-free survival was met. Kisqali plus hormone therapy significantly reduced the risk of recurrence compared to standard hormone therapy alone in the adjuvant setting, with a consistent benefit in patients with early stage II and III breast cancer. Copyright (c) 2023 CercleFinance.com. All rights reserved. |
23/07/2025 07:25
Soitecbaisse organique de 16% du CA au 1er trimestre 23/07/2025 07:07 DBV Technologiesnouveau DRH nommé 22/07/2025 18:32 flatexDEGIRObénéfice net trimestriel en hausse de 28% 22/07/2025 18:27 Drone Voltse renforce dans le 'LiDAR' avec une acquisition ciblée 22/07/2025 18:20 Alstomva fournir des systèmes de propulsion pour 435 métros à New York 22/07/2025 18:13 Ubisoftrésultats trimestriels 'contrastés' estime le DG Tous les articles sociétés |
